首頁 > 市場調查報告書 > 醫療設備

生技設備 3D列印

市場調查報告書

商品編碼

1542974

全球生物列印器官移植市場 - 2024-2031

Global Bioprinting on Organ Transplant Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

器官移植市場的全球生物印刷在2023年達到10.5億美元，預計到2031年將達到27.3億美元，在2024-2031年預測期間複合年成長率為13.2%。

器官/組織的體外生物製造由兩個需求驅動，即器官移植和精確的組織模型。生物列印，也稱為3D (3D) 列印，是一種用於開發許多組織/器官的技術，例如肝臟、皮膚和心臟。該技術與使用生物材料、活細胞和生物分子列印結構有關。生物人工器官的創造為未來的器官移植計畫開闢了新的途徑。

全球對器官移植的需求迅速成長。由於重要器官衰竭的發生率增加以及移植後結果的成功率較高，因此需要器官移植。在全球範圍內，由於移植器官的需求增加和供應不足，出現了嚴重的器官短缺危機。 3D生物列印以細胞或其他生物材料為印刷油墨，根據仿生形態、生物功能和細胞微環境的要求，透過積層製造方法列印出具有生物功能的複雜3D生物結構。

市場動態：

司機

器官移植需求增加

全球器官移植市場對生物列印的需求是由多種因素所驅動的。人造器官和器官移植需求的增加推動了市場的成長。

此外，技術發展和研究工作資金分配將推動器官移植市場對全球生物列印的需求。例如，根據移植.hrsa.gov，2023 年有 46,632 例器官移植手術來自活體和已故捐贈者。例器官移植。已故捐贈者的器官移植數量為 39,679 例。這比 2022 年成長了 8.9%，也是連續第十一年創紀錄。

例如，根據nih.gov 2024 年2 月發布的一篇文章，印度每年進行17,000-18,000 例實體器官移植，僅次於美國和中國，位居世界第一，但移植率仍落後於幾個高收入國家每百萬人口（0.65）。這一領域已經取得了進展，例如從已故捐贈者身上獲取器官的情況有所改善，每個捐贈者的平均器官移植數量從 2016 年的 2.43 例增加到 2022 年的 3.05 例。

限制

器官移植相關的副作用和風險、人造器官的高成本、熟練專業人員的短缺以及新技術核准的嚴格監管要求等因素預計將阻礙市場。

細分市場分析

全球器官移植生物列印市場根據製程、生物墨水、使用的細胞類型、最終用戶和地區進行細分。

基於擠壓的生物列印領域約佔全球器官移植生物列印市場佔有率的47.8%

基於擠出的生物列印領域預計將在預測期內佔據最大的市場佔有率。在這一領域，政府監管的發展以及私營製造商用於研究工作的資金不斷增加將推動該市場的發展。

基於擠壓的生物列印是一種強大的3D (3D) 生物列印技術，為器官製造提供了獨特的機會。這項技術在過去十年中發展迅速。基於擠出的生物列印在列印各種生物化合物或設備方面提供了巨大的多功能性，包括細胞、組織、類器官和微流體設備，可應用於基礎研究、藥劑學、藥物測試、移植和臨床用途。基於擠出的生物列印為列印各種生物墨水提供了極大的靈活性，包括組織球體、細胞沉澱、微載體、去細胞基質成分和載有細胞的水凝膠。

例如，2022 年 4 月，芬蘭生物列印新創公司 Brinter 宣佈為其生物印表機推出一款新型擠出型 Visco Bio 醫用列印頭。與 Puredyne 密切合作推出的新型模組化列印頭向市場提供創新技術，可將昂貴的醫療級材料的浪費降至最低。

市場地域佔有率

北美約佔全球生物列印器官移植市場佔有率的42.5%

預計北美地區將在預測期內佔據最大的市場佔有率。該地區對器官移植的需求不斷成長以及技術進步有助於推動市場發展。

例如，根據hrsa.gov發表的文章，2024年1月，死亡器官捐贈者超過16,000人，創年度新紀錄，延續了13年的年度紀錄趨勢。進行了超過 46,000 例器官移植，繼續保持每年創紀錄的趨勢。超過 10,000 名移植接受者是黑人和非西班牙裔。首次實施肝臟移植手術超過1萬例。首次實施肺移植3000餘例。腎臟和心臟移植也創下了新的年度記錄。

例如，2023年11月，Cellink和Ossiform建立了策略夥伴關係，聯手將基於Ossiform現有生物材料的可列印生物墨水商業化。該資料將於 2024 年開始銷售，並將透過 Cellink 的商業管道獨家分銷。 Cellink 和 Ossiform 計畫利用協同效應，向市場推出一種用於骨骼研究的高功能生物墨水。此次合作也涉及其他材料，包括臨床級生物墨水。

Biomanufacturing of organs/tissues in vitro has been driven by two needs, i.e., organ transplantation and accurate tissue models. Bioprinting, also known as three-dimensional (3D) printing, is a technique used to develop many tissues/organs, such as the liver, skin, and heart. This technique is associated with printing structures using biomaterials, viable cells, and biomolecules. The creation of bioartificial organs has opened new avenues for future organ transplantation programs.

The demand for organ transplants has increased rapidly worldwide. Organ transplants are required due to the increased incidence of vital organ failure and the higher success rate of post-transplant outcomes. Globally, a major organ shortage crisis has emerged due to higher demand and insufficient supply of organs for transplant. 3D bioprinting uses cells or other bio-materials as printing inks to print complex 3D biological structures with biological functions according to the requirements of the bionic morphology, biological function, and cellular microenvironment through additive manufacturing methods.

Market Dynamics: Drivers

Increasing need for organ transplantation

The demand for global bioprinting on organ transplantation market is driven by multiple factors. The increase in the need for artificial organs and organ transplantation propels the market growth.

Furthermore, the demand for global bioprinting on organ transplantation market will be fueled by technological developments and funding allotted for research work. For instance, according to transplant.hrsa.gov, There were 46,632 organ transplants performed from both living and deceased donors in 2023. This represents an 8.7 percent increase over 2022 and a 12.7 percent increase over 2021, which was the first year with more than 40,000 organ transplants. There were 39,679 organ transplants from deceased donors. This represents an 8.9 percent increase over 2022 and marks the eleventh consecutive record-setting year.

For instance, according to an article posted by nih.gov in February 2024, India sees 17,000-18,000 solid organ transplants performed every year, the most in the world after the US and China, but remains behind several high-income countries in transplantation rates per million population (0.65). There has been progress in this area, such as an improvement in the harvesting of organs from deceased donors, with the average number of organ transplants per donor increasing from 2.43 in 2016 to 3.05 in 2022.

Restraints

Factors such as side effects and risks related to organ transplantation, the high cost of artificial organs, the shortage of skilled professionals, and stringent regulatory requirements for the approval of new techniques are expected to hamper the market.

Market Segment Analysis

The global bioprinting on organ transplantation market is segmented based on process, bioink, cell type used, end-user, and region.

The segment extrusion-based bioprinting accounted for approximately 47.8% of the global bioprinting on organ transplantation market share

The extrusion-based bioprinting segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research work would drive this market.

Extrusion-based bioprinting is a powerful three-dimensional (3D) bioprinting technology that provides unique opportunities for use in organ fabrication. This technology has grown rapidly during the last decade. Extrusion-based bioprinting provides great versatility in printing various biological compounds or devices, including cells, tissues, organoids, and microfluidic devices that can be applied in basic research, pharmaceutics, drug testing, transplantation, and clinical uses. Extrusion-based bioprinting offers great flexibility in printing a wide range of bioinks, including tissue spheroids, cell pellets, microcarriers, decellularized matrix components, and cell-laden hydrogels.

For instance, in April 2022, Finland-based bioprinting startup Brinter announced the launch of a new extrusion-based Visco Bio medical printhead for its bioprinters. New modular printheads introduced in close collaboration with Puredyne, who provides innovative technologies to the market, allow waste of expensive medical grade materials to be kept to a minimum.

Market Geographical Share

North America accounted for approximately 42.5% of the global bioprinting on organ transplantation market share

North America region is expected to hold the largest market share over the forecast period. The increasing demand for organ transplantation, and technological advancements, in this region, help to propel the market.

For instance, according to an article published by hrsa.gov, in January 2024, More than 16,000 deceased organ donors, a new annual record and a continuation of a 13-year annual record trend. More than 46,000 organ transplants were performed, continuing an annual record-setting trend. More than 10,000 transplant recipients were Black, and non-Hispanic. More than 10,000 liver transplants were performed for the first time. More than 3,000 lung transplants were performed for the first time. New annual records are also set for kidney and heart transplants.

For instance, in November 2023, Cellink and Ossiform entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform's existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through Cellink's commercial channels. Cellink and Ossiform are planning to capitalize on synergies and bring to the market a highly functional bio-ink for bone-based research. The partnership has scope for additional materials, including clinical-grade bioinks.

Market Segmentation

By Process

Inkjet Bioprinting
Laser-Assisted Bioprinting
Extrusion-Based Bioprinting
Acoustic Bioprinting
Magnetic Bioprinting
Vatphotopolymerization-based bioprinting
Others

By Bioink

PEG diacrylate
Nanocellulose
Collagen I
Graphene
Others

By Cell Type Used

iPS Cells
Mesenchymal Stem Cells
Keratinocytes
Neural Stem Cell
Others

By End-User

Hospitals
Research and Educational Institutions
Specialty Clinics
Organ Transplantation Centers
Others

By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the global bioprinting on organ transplantation market include 3D Systems Corporation, Protolabs, Materialise, Stratasys, General Electric Company, Desktop Metal Inc., Aspect Biosystems Ltd., EnvisionTEC Llc., Ibio Inc., and Printivo among others.

Key Developments

In September 2022, 3D Systems announced the formation of a new, wholly-owned company called Systemic Bio(TM), a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development. Systemic Bio will leverage 3D Systems' breakthrough, production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells.
In October 2023, Carcinotech and 3D bioprinting firm CELLINK announced a partnership to accelerate cancer drug development with 3D bio-printed tumor models. The partnership will focus on the development and commercialization of cutting-edge protocols for the biofabrication of 3D bio-printed tumor models using cancer cell lines. These models are designed to significantly improve accuracy and speed up drug development processes, ultimately reducing development costs and enhancing research output. The protocols will be made available for use on CELLINK's state-of-the-art BIO CELLX system.
In June 2022, CollPlant a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market.

Why Purchase the Report?

To visualize the global bioprinting on organ transplantation market segmentation based on, process, bioink, cell type used, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global bioprinting on organ transplantation market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global bioprinting on organ transplantation market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Process
3.2. Snippet by Bioink
3.3. Snippet by Cell Type Used
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Need for Organ Transplantation
  - 4.1.1.2. Technological Advancements
  - 4.1.1.3. Hefty Funds Allotted for the Research Work
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Artificial Organs
  - 4.1.2.2. Shortage of Skilled Professionals
  - 4.1.2.3. Stringent Regulatory Requirements
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. By Process

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 6.1.2. Market Attractiveness Index, By Process
6.2. Inkjet Bioprinting*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Laser-Assisted Bioprinting
6.4. Extrusion-Based Bioprinting
6.5. Acoustic Bioprinting
6.6. Magnetic Bioprinting
6.7. Vatphotopolymerization-based Bioprinting
6.8. Others

7. By Bioink

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioink
- 7.1.2. Market Attractiveness Index, By Bioink
7.2. PEG Diacrylate*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Nanocellulose
7.4. Collagen I
7.5. Graphene
7.6. Others

8. By Cell Type Used

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type Used
- 8.1.2. Market Attractiveness Index, By Cell Type Used
8.2. iPS Cells*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Mesenchymal Stem Cells
8.4. Keratinocytes
8.5. Neural Stem Cells
8.6. Others

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research and Educational Institutions
9.4. Speciality Clinics
9.5. Organ Transplantation Centers
9.6. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioink
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type Used
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioink
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type Used
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioink
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type Used
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioink
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type Used
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Process
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioink
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type Used
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. 3D Systems Corporation *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Cell Ink
12.3. Materialise
12.4. Stratasys
12.5. General Electric Company
12.6. Desktop Metal Inc.
12.7. Aspect Biosystems Ltd.
12.8. EnvisionTEC Llc.
12.9. Ibio Inc.
12.10. Printivo (*LIST NOT EXHAUSTIVE)